Valuation: Aquestive Therapeutics, Inc.

Market Cap 551M 483M 445M 417M 781M 51.95B 798M 5.35B 2.07B 25.68B 2.07B 2.02B 89.03B P/E 2026 *
-10.8x
P/E 2027 * -11.3x
Enterprise Value 466M 408M 376M 352M 661M 43.93B 675M 4.52B 1.75B 21.71B 1.75B 1.71B 75.29B EV / Sales 2026 *
9.22x
EV / Sales 2027 * 7.66x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week-6.79%
Current month+9.20%
1 month+6.55%
3 months+4.28%
6 months-26.47%
Current year-32.04%
1 week 4.16
Extreme 4.16
5.18
1 month 3.85
Extreme 3.85
5.18
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
06-23Fiscal year

Director

75,000 0.0598%
06-15Sell

Chief Executive Officer

-25,000 0.0199%
06-10Free

Director

50,500 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%-6.79%+35.08%+139.89% 560M
+7.13%+9.97%+52.48%+163.30% 1,006B
+3.99%+11.50%+67.23%+53.89% 589B
+4.20%+17.03%+36.66%+86.40% 430B
+0.99%+5.11%+29.26%+21.27% 331B
+1.82%+8.85%+39.72%+25.35% 288B
+0.22%+6.98%+32.93%+39.24% 285B
+0.73%+13.51%-26.95%-41.57% 213B
+1.56%+6.14%+27.82%+57.78% 190B
+3.26%+3.33%+20.72%+65.07% 154B
Average +1.69%+4.84%+31.49%+61.06% 348.63B
Weighted average by Cap. +2.25%+5.38%+40.57%+77.69%

Financials

2026 *2027 *
Net sales 50.51M 44.29M 40.82M 38.22M 71.67M 4.76B 73.16M 491M 190M 2.35B 190M 186M 8.17B 71.92M 63.06M 58.12M 54.42M 102M 6.78B 104M 699M 270M 3.35B 270M 264M 11.63B
Net income -50.65M -44.41M -40.93M -38.32M -71.86M -4.78B -73.35M -492M -190M -2.36B -190M -186M -8.19B -47.99M -42.08M -38.79M -36.31M -68.1M -4.53B -69.51M -466M -180M -2.24B -180M -176M -7.76B
Net Debt -85M -74.53M -68.7M -64.32M -121M -8.02B -123M -826M -319M -3.96B -319M -312M -13.74B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
26/06/26 $4.390 -1.68% 7,357,827
25/06/26 $4.465 -10.52% 5,171,645
24/06/26 $4.990 -0.80% 2,226,196
23/06/26 $5.030 +6.57% 2,988,647
22/06/26 $4.720 +0.21% 1,937,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.390USD
Average target price
8.889USD
Spread / Average Target
+102.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock